Home » FDA APPROVES AMBIEN CR CIV
FDA APPROVES AMBIEN CR CIV
Sanofi-aventis has announced that the FDA has approved Ambien CR CIV, a new extended-release formulation of the prescription sleep aid, Ambien CIV, for the treatment of insomnia.
Ambien CR is non-narcotic and a non-benzodiazepine, formulated to offer a similar safety profile to Ambien with a new indication for sleep maintenance, in addition to sleep induction.
Ambien CR helps people with insomnia fall asleep fast and maintain sleep with no significant decrease in next-day performance. Ambien CR, a bilayered tablet, is delivered in two stages -- the first layer dissolves quickly to induce sleep, while the second layer is released more gradually into the body to help provide more continuous sleep.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May